The biggest winner on the market Friday was Endocyte (NASDAQ:ECYT)by a long shot, as shares absolutely exploded, closing upwards of 90% for the day. The market was celebrating a successful phase 2 clinical trial of the company's drug vintafolide in its lung cancer indication. When combined with chemotherapy, the drug gave patients a 25% benefit both in progression-free survival rates and overall survival rates. In addition, the company received EU approval for vintafolide in the treatment of ovarian cancer.
These two catalysts have caused analyst price targets to jump, with Piper Jaffray coming out and raising its target on the stock to $36; shares currently sit at $28. In this segment from Friday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass discuss Endocyte's partnership with Merck (NYSE:MRK) on the drug, as well as just how much blockbuster potential the drug could have, and why even after a near double the stock is filled with upside.
Looking for more explosive growth stocks?
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
David Williamson owns shares of Merck. Michael Douglass and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.